Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapy
1.1.2. Drug class
1.1.3. End-use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapy outlook
2.2.2. Drug class outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Actinic Keratosis Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Actinic Keratosis Treatment Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis
4.1. Actinic Keratosis Treatment Market: Key Takeaways
4.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Topical
4.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Surgery
4.4.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Photodynamic Therapy
4.5.1. Photodynamic therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis
5.1. Actinic Keratosis Treatment Market: Key Takeaways
5.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Nucleoside Metabolic Inhibitor
5.3.1. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. NSAIDS
5.4.1. NSAIDS market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immune Response Modifiers
5.5.1. Immune response modifiers market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Photoenhancers
5.6.1. Photoenhancers market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Actinic Keratosis Treatment Market: End-use Estimates & Trend Analysis
6.1. Actinic Keratosis Treatment Market: Key Takeaways
6.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Hospitals
6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Private Clinics Delivery
6.4.1. Private clinics delivery market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Homecare
6.5.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Actinic Keratosis Treatment Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Almirall S.A.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. LEO Pharma A/S
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Sun Pharmaceutical Industries Ltd.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Novartis AG
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. GALDERMA
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Ortho Dermatologics (Bausch Health Companies Inc.)
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. BIOFRONTERA AG
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Hill Dermaceuticals, Inc.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/